Scroll

afatinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
tyrosine kinase inhibitors	4318	850140-72-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: afatinib tovok afatinib dimaleate gilotrif BIBW2992 afatinib maleate	A quinazoline and butenamide derivative that acts as a tyrosine kinase inhibitor of epidermal growth factor receptors (ERBB RECEPTORS) and is used in the treatment of metastatic NON-SMALL CELL LUNG CANCER. Molecular weight: 485.94 Formula: C24H25ClFN5O3 CLOGP: 4.34 LIPINSKI: 0 HAC: 8 HDO: 2 TPSA: 88.61 ALOGS: -4.58 ROTB: 8 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

afatinib
tovok
afatinib dimaleate
gilotrif
BIBW2992
afatinib maleate

A quinazoline and butenamide derivative that acts as a tyrosine kinase inhibitor of epidermal growth factor receptors (ERBB RECEPTORS) and is used in the treatment of metastatic NON-SMALL CELL LUNG CANCER.

Molecular weight: 485.94
Formula: C24H25ClFN5O3
CLOGP: 4.34
LIPINSKI: 0
HAC: 8
HDO: 2
TPSA: 88.61
ALOGS: -4.58
ROTB: 8

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
40	mg	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Hosey CM, Chan R, Benet LZ
S (Water solubility)	14.36 mg/mL	Bocci G, Oprea TI, Benet LZ

Showing 1 to 2 of 2 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
July 12, 2013	FDA	BOEHRINGER INGELHEIM
Sept. 25, 2013	EMA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	1866.95	28.61	616	8301	81505	63398600
Diarrhoea	1250.20	28.61	917	8000	714449	62765656
Paronychia	796.22	28.61	179	8738	5386	63474719
Metastases to central nervous system	346.55	28.61	111	8806	12994	63467111
Stomatitis	273.07	28.61	194	8723	138531	63341574
Dermatitis acneiform	225.77	28.61	64	8853	4932	63475173
Rash	220.74	28.61	327	8590	560544	62919561
Decreased appetite	182.16	28.61	199	8718	250853	63229252
Metastases to meninges	157.72	28.61	42	8875	2560	63477545
Dehydration	153.50	28.61	153	8764	173201	63306904

Showing 1 to 10 of 43 entries

Previous1 2 3 4 5Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	1324.12	33.74	474	4096	87572	34864789
Diarrhoea	592.40	33.74	447	4123	389465	34562896
Paronychia	357.39	33.74	84	4486	3321	34949040
Metastases to central nervous system	279.75	33.74	83	4487	8122	34944239
Rash	262.21	33.74	222	4348	222530	34729831
Stomatitis	228.15	33.74	111	4459	42403	34909958
EGFR gene mutation	128.94	33.74	22	4548	155	34952206
Dermatitis acneiform	113.11	33.74	39	4531	6150	34946211
Interstitial lung disease	92.68	33.74	73	4497	65209	34887152
Decreased appetite	87.63	33.74	108	4462	166284	34786077

Showing 1 to 10 of 19 entries

Previous1 2Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	2677.53	24.52	936	11333	135054	79597065
Diarrhoea	1567.22	24.52	1185	11084	879304	78852815
Paronychia	1029.56	24.52	239	12030	7569	79724550
Metastases to central nervous system	474.62	24.52	152	12117	16223	79715896
Stomatitis	440.15	24.52	276	11993	146481	79585638
Rash	415.73	24.52	475	11794	577883	79154236
Dermatitis acneiform	323.63	24.52	101	12168	9892	79722227
EGFR gene mutation	245.24	24.52	45	12224	419	79731700
Decreased appetite	227.50	24.52	271	11998	342147	79389972
Metastases to meninges	184.84	24.52	52	12217	3549	79728570

Showing 1 to 10 of 58 entries

Previous1 2 3 4 5 6Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	L01EB03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:38637	tyrosine kinase inhibitors
FDA EPC	N0000175605	Kinase Inhibitor
FDA MoA	N0000175076	Protein Kinase Inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D047428	Protein Kinase Inhibitors

Showing 1 to 8 of 8 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Non-small cell lung cancer, positive for epidermal growth factor receptor expression	indication	426964009

Showing 1 to 1 of 1 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.1	acidic
pKa2	8.94	Basic
pKa3	4.09	Basic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 20MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	9539258	Nov. 9, 2026	TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY
EQ 30MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	9539258	Nov. 9, 2026	TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY
EQ 40MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	9539258	Nov. 9, 2026	TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY

Showing 1 to 3 of 3 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 20MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	April 15, 2023	TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY
EQ 20MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	Oct. 15, 2023	PEDIATRIC EXCLUSIVITY
EQ 20MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	Jan. 12, 2025	FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR (EGFR) MUTATIONS OTHER THAN EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
EQ 20MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	April 7, 2025	REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTSFROM CLINICAL STUDY 1200.120, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
EQ 20MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	July 12, 2025	PEDIATRIC EXCLUSIVITY
EQ 20MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	Oct. 7, 2025	PEDIATRIC EXCLUSIVITY
EQ 30MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	April 15, 2023	TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY
EQ 30MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	Oct. 15, 2023	PEDIATRIC EXCLUSIVITY
EQ 30MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	Jan. 12, 2025	FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR (EGFR) MUTATIONS OTHER THAN EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
EQ 30MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	April 7, 2025	REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTSFROM CLINICAL STUDY 1200.120, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST

Showing 1 to 10 of 18 entries

Previous1 2Next

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN	INHIBITOR	Kd	10	CHEMBL	CHEMBL
Receptor tyrosine-protein kinase erbB-4	Kinase	Q15303	ERBB4_HUMAN	INHIBITOR	Kd	8.20	CHEMBL	CHEMBL
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN	INHIBITOR	Kd	8.30	CHEMBL	CHEMBL
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN		Kd	6.24	CHEMBL
Receptor-type tyrosine-protein kinase FLT3	Kinase	P36888	FLT3_HUMAN		Kd	5.85	CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Kinase	P15735	PHKG2_HUMAN		Kd	6.33	CHEMBL
Myosin light chain kinase, smooth muscle	Kinase	Q15746	MYLK_HUMAN		Kd	4.50	CHEMBL
Tyrosine-protein kinase HCK	Kinase	P08631	HCK_HUMAN		Kd	5.66	CHEMBL
Mitogen-activated protein kinase 10	Kinase	P53779	MK10_HUMAN		Kd	5.70	CHEMBL
Hepatocyte growth factor receptor	Kinase	P08581	MET_HUMAN		Kd	5.66	CHEMBL

Showing 1 to 10 of 42 entries

Previous1 2 3 4 5Next

External reference:

Show entries

Search:

ID	Source
0WM	PDB_CHEM_ID
015117	NDDF
015118	NDDF
10184653	PUBCHEM_CID
1430268	RXNORM
204142	MMSL
29566	MMSL
4032662	VUID
4032662	VANDF
4032663	VANDF

Showing 1 to 10 of 27 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Gilotrif	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0137	TABLET, FILM COATED	30 mg	ORAL	NDA	31 sections
Gilotrif	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0137	TABLET, FILM COATED	30 mg	ORAL	NDA	31 sections
Gilotrif	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0137	TABLET, FILM COATED	30 mg	ORAL	NDA	31 sections
Gilotrif	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0138	TABLET, FILM COATED	40 mg	ORAL	NDA	31 sections
Gilotrif	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0138	TABLET, FILM COATED	40 mg	ORAL	NDA	31 sections
Gilotrif	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0138	TABLET, FILM COATED	40 mg	ORAL	NDA	31 sections
Gilotrif	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0141	TABLET, FILM COATED	20 mg	ORAL	NDA	31 sections
Gilotrif	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0141	TABLET, FILM COATED	20 mg	ORAL	NDA	31 sections
Gilotrif	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0141	TABLET, FILM COATED	20 mg	ORAL	NDA	31 sections

Showing 1 to 9 of 9 entries

Previous1Next